Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | NPY2R | P49146 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11724568 | 0.84 | ESR1 (0.36) | TAAR1CYP2D6CYP3A4DRD2DRD4 | |
| SCHEMBL5645124 | 0.82 | CYP2D6 (0.49) | TAAR1CYP2D6CYP3A4DRD2DRD4 | |
| SCHEMBL11724581 | 0.82 | CYP2C19 (0.47) | TAAR1CYP2D6CYP3A4DRD2DRD4 | |
| SCHEMBL9447336 | 0.80 | TSHR (0.46) | TAAR1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL2815949 | 0.78 | MAPT (0.47) | TAAR1CYP3A4MAPK1CYP2C19RAB9A | |
| SCHEMBL31310650 | 0.78 | CYP2C19 (0.42) | TAAR1CYP2D6CYP3A4DRD2DRD4 | |
| SCHEMBL11421695 | 0.78 | TAAR1 (0.43) | TAAR1CYP2D6CYP3A4DRD2DRD4 | |
| SCHEMBL4679692 | 0.78 | SHBG (0.32) | TAAR1ESR1ESR2 | |
| SCHEMBL955513 | 0.78 | CYP2C19 (0.42) | TAAR1CYP2D6CYP3A4DRD2DRD4 | |
| SCHEMBL3045851 | 0.78 | CYP2A6 (0.33) | TAAR1ALDH1A1ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2943495-B1 | PYRIMIDONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | SAVIRA PHARMACEUTICALS GMBH (AT) | 2016-12-28 | — | — | EP | disclosed |
| EP-2943495-A1 | PYRIMIDONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | Savira Pharmaceuticals GmbH (AT) | 2015-11-18 | — | — | EP | disclosed |
| CN-104918942-A | Pyrimidone derivatives and their use for treating, ameliorating or preventing viral diseases | SAVIRA PHARMACEUTICALS GMBH | 2015-09-16 | — | — | CN | disclosed |
| US-9045486-B2 | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease | SAVIRA PHARMACEUTICALS GMBH (AT) | 2015-06-02 | — | — | US | disclosed |
| US-9045486-B2 | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease | SAVIRA PHARMACEUTICALS GMBH (AT) | 2015-06-02 | — | — | US | disclosed |
| US-9045486-B2 | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease | SAVIRA PHARMACEUTICALS GMBH (AT) | 2015-06-02 | — | — | US | disclosed |
| WO-2014108406-A1 | PYRIMIDONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | SAVIRA PHARMACEUTICALS GMBH (AT) | 2014-07-17 | — | — | WO | disclosed |
| WO-2014108406-A1 | PYRIMIDONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | SAVIRA PHARMACEUTICALS GMBH (AT) | 2014-07-17 | — | — | WO | disclosed |
| US-20140194431-A1 | PYRIMIDONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | SAVIRA PHARMACEUTICALS GMBH (AT) | 2014-07-10 | — | — | US | disclosed |
| US-20140194431-A1 | PYRIMIDONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | SAVIRA PHARMACEUTICALS GMBH (AT) | 2014-07-10 | — | — | US | disclosed |
| EP-0790998-B1 | AZO DERIVATIVES OF 5-AMINOSALICYLIC ACID FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE | URIACH & CIA SA J (ES) | 2001-01-17 | — | — | EP | disclosed |
| EP-0738269-B1 | PIPERIDINE DERIVATIVES WITH PAF ANTAGONIST ACTIVITY | URIACH & CIA SA J (ES) | 2000-04-26 | — | — | EP | disclosed |
| US-5852209-A | Process for optically resolving 2-(3-benzoylphenyl) propionic acid | NAGASE & CO., LTD. (JP) | 1998-12-22 | — | — | US | disclosed |
| US-5747477-A | INFLAMMATORY BOWEL DISEASE, GASTROINTESTINAL DISORDERS, CROHN*S DISEASE | J. URIACH & CIA S.A. (ES) | 1998-05-05 | — | — | US | disclosed |
| US-5705504-A | PLATELET ACTIVATING FACTOR | J. URIACH & CIA, S.A. (ES) | 1998-01-06 | — | — | US | disclosed |
| EP-0790998-A1 | AZO DERIVATIVES OF 5-AMINOSALICYLIC ACID FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE | J. URIACH & CIA. S.A. (ES) | 1997-08-27 | — | — | EP | disclosed |
| WO-1997009329-A1 | AZO DERIVATIVES OF 5-AMINOSALICYLIC ACID FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE | J. URIACH & CIA. S.A. (ES) | 1997-03-13 | — | — | WO | disclosed |
| EP-0738269-A1 | NOVEL PIPERIDINE DERIVATIVES WITH PAF ANTAGONIST ACTIVITY | J. URIACH & CIA. S.A. (ES) | 1996-10-23 | — | — | EP | disclosed |
| WO-1996014317-A1 | NOVEL PIPERIDINE DERIVATIVES WITH PAF ANTAGONIST ACTIVITY | J. URIACH & CIA. S.A. (ES) | 1996-05-17 | — | — | WO | disclosed |
| EP-0703212-A1 | Process for optically resolving 2-(3-benzoylphenyl) propionic acid | NAGASE & COMPANY, LTD. (JP) | 1996-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194431-A1 | PYRIMIDONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | TPMT, XDH, DPYD | TAAR1 1163/4885CYP2D6 10/4885CYP3A4 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.